PendingISSN (Online)
Volume 1 , Issue 1 , PP: 45-54, 2024 | Cite this article as | XML | Html | PDF | Full Length Article
Marwa M. Eid 1 * , Wei Hong Lim 2
Doi: https://doi.org/10.54216/MOR.010104
Chronic liver disease (CLD) is a group of conditions for which up to half of the global population remains at risk and causes serious complications: liver cirrhosis and liver cancer. Therefore, early diagnosis and proper treatment of these diseases enhance the prognosis of patients suffering from CLD. This review paper explores how machine learning (ML) techniques are used in practice to diagnose, prognosis, and treat chronic liver diseases. Continuing with more specific examples of collected data from the results of several studies, their more comprehensive implementation is expected to improve the respective management processes and the detection of liver disease in patients more accurately. The review further discusses the various ML methods, including supervised and unsupervised learning, neural network, and ensemble learning, also applied to the estimation of risk felt by the patients, suggesting a course of treatment or how far the disease has progressed. While the inclusion of ML technology in the field of Hepatology is progressing well, some issues like model diversity, applicability of models, and concerns about ethics still pose challenges. This paper points out the importance of working in teams from various fields to develop appropriate mechanisms for dealing with these issues and adequately use ML for clinics. In conclusion, the results indicate that there is a possibility that ML will change the management of chronic liver diseases, which in turn will lead to the development of innovative treatment methods and better patient management.
Persistent hepatic illnesses , Computational techniques , Identification , Prediction , Management and evidence-based methods
[1] S. Feng et al., “Current Status and Analysis of Machine Learning in Hepatocellular Carcinoma,” J Clin Transl Hepatol, vol. 11, no. 5, p. 1184, Oct. 2023, doi: 10.14218/JCTH.2022.00077S.
[2] H. W. Lee, J. J. Y. Sung, and S. H. Ahn, “Artificial intelligence in liver disease,” J Gastroenterol Hepatol, vol. 36, no. 3, pp. 539–542, Mar. 2021, doi: 10.1111/JGH.15409.
[3] A. Abdulrahman, .. Z. M., A. M. Zaki, F. H. H.Rizk, M. M. Eid, and E.-S. M. EL EL-Kenawy, “Exploring Optimization Algorithms: A Review of Methods and Applications,” Journal of Artificial Intelligence and Metaheuristics, vol. 7, no. 2, pp. 08–17, 2024, doi: 10.54216/JAIM.070201.
[4] M. Ai-Hasani, L. R. Sultan, H. Sagreiya, T. W. Cary, M. B. Karmacharya, and C. M. Sehgal, “Machine learning improves early detection of liver fibrosis by quantitative ultrasound radiomics,” IEEE Int Ultrason Symp, vol. 2022, p. 10.1109/ius54386.2022.9957180, 2022, doi: 10.1109/IUS54386.2022.9957180.
[5] M. Li, X. Song, C. Xu, and C. Yu, “Response to the clinical significance and prognostic value of 3-mercaptopyruvate sulfurtransferase in hepatocellular carcinoma,” Liver International, vol. 42, no. 7, pp. 1696–1696, Jul. 2022, doi: 10.1111/LIV.15280.
[6] G. Chongo and J. Soldera, “Use of machine learning models for the prognostication of liver transplantation: A systematic review,” World J Transplant, vol. 14, no. 1, p. 88891, Mar. 2024, doi: 10.5500/WJT.V14.I1.88891.
[7] A. C. Filiberto, I. L. Leeds, and T. J. Loftus, “Editorial: Machine Learning in Clinical Decision-Making,” Front Digit Health, vol. 3, p. 784495, Nov. 2021, doi: 10.3389/FDGTH.2021.784495/BIBTEX.
[8] S. Hashem et al., “Comparison of Machine Learning Approaches for Prediction of Advanced Liver Fibrosis in Chronic Hepatitis C Patients,” IEEE/ACM Trans Comput Biol Bioinform, vol. 15, no. 3, pp. 861–868, May 2018, doi: 10.1109/TCBB.2017.2690848.
[9] L. Parisi, N. Ravichandran, and M. L. Manaog, “A novel hybrid algorithm for aiding prediction of prognosis in patients with hepatitis,” Neural Comput Appl, vol. 32, no. 8, pp. 3839–3852, Apr. 2020, doi: 10.1007/S00521-019-04050-X/TABLES/5.
[10] Y. Xu et al., “Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein,” Ann Hepatol, vol. 29, no. 6, p. 101540, Nov. 2024, doi 10.1016/J.AOHEP.2024.101540.
[11] H. I. Shousha, A. H. Awad, D. A. Omran, M. M. Elnegouly, and M. Mabrouk, “Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C,” Jpn J Infect Dis, vol. 71, no. 1, pp. 51–57, 2018, doi: 10.7883/YOKEN.JJID.2017.089.
[12] A. Kukkar and J. K. Sandhu, “An Automatic Diagnosis System Based on Machine Learning Models for Predicting Hepatitis C from Blood Samples,” Signals and Communication Technology, vol. Part F3355, pp. 91–108, 2024, doi: 10.1007/978-3-031-56818-3_6/FIGURES/10.
[13] S. Tanvir Fayaz, G. S. Tejanmayi, Y. Kanaka Ruthvi, S. Vijaya Shetty, S. U. Shenoy, and G. Bhat, “Prediction of Liver Patients Using Machine Learning Algorithms,” Lecture Notes in Electrical Engineering, vol. 789, pp. 135–145, 2022, doi: 10.1007/978-981-16-1338-8_12/TABLES/4.
[14] J. S. Sartakhti, M. H. Zangooei, and K. Mozafari, “Hepatitis disease diagnosis using a novel hybrid method based on support vector machine and simulated annealing (SVM-SA),” Comput Methods Programs Biomed, vol. 108, no. 2, pp. 570–579, Nov. 2012, doi: 10.1016/J.CMPB.2011.08.003.
[15] J. Jin et al., “Deep learning radiomics model accurately predicts hepatocellular carcinoma occurrence in chronic hepatitis B patients: a five-year follow-up,” Am J Cancer Res, vol. 11, no. 2, p. 576, 2021, Accessed: Oct. 27, 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC7868753/
[16] A. Lukáčová, F. Babič, Z. Paraličová, and J. Paralič, “How to increase the effectiveness of the hepatitis diagnostics by means of appropriate machine learning methods,” Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), vol. 9267, pp. 81–94, 2015, doi: 10.1007/978-3-319-22741-2_8/FIGURES/6.
[17] A. H. Kayvanjoo, M. Ebrahimi, and G. Haqshenas, “Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms,” BMC Res Notes, vol. 7, no. 1, pp. 1–11, Aug. 2014, doi: 10.1186/1756-0500-7-565/TABLES/2.
[18] C. Vijayalakshmi and S. Pakkir Mohideen, “Survival prediction model with lion optimization for Hepatitis-B patients using supervised and unsupervised learning algorithm,” Measurement: Sensors, vol. 32, p. 100958, Apr. 2024, doi: 10.1016/J.MEASEN.2023.100958.
[19] S. Qiu et al., “Predicting the 28-day prognosis of acute-on-chronic liver failure patients based on machine learning,” Digestive and Liver Disease, Jul. 2024, doi: 10.1016/J.DLD.2024.06.029.
[20] Y. Anyin, L. Jianping, L. Mengru, Z. Hong, Z. Xulei, and W. Lianping, “Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma,” Diagn Pathol, vol. 19, no. 1, pp. 1–10, Dec. 2024, doi: 10.1186/S13000-024-01528-8/TABLES/3.
[21] Y. Anyin, L. Jianping, L. Mengru, Z. Hong, Z. Xulei, and W. Lianping, “Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma,” Diagn Pathol, vol. 19, no. 1, pp. 1–10, Dec. 2024, doi: 10.1186/S13000-024-01528-8/TABLES/3.
[22] A. Babu, S. Sri Krishna, K. S. Saran, and B. Aarthi, “Categorization and Forecasting of Hepatitis C Diagnosis via an Unconventional Consensus Classifier,” International Journal of Advance Research, pp. 2454–132, 2024, Accessed: Oct. 27, 2024. [Online]. Available: https://www.ijariit.com
